Crinetics Pharmaceuticals (FRA:6Z4) Tariff Resilience Score: 7/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Z4 Crinetics Pharmaceuticals Inc FRA:6Z4
50 GF Score
Price €70.90
GF Value €629.53
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Tariff Resilience Score?

Crinetics Pharmaceuticals FRA:6Z4 -1.23% 50 Tariff Resilience Score is 7 as of Jul. 20, 2026. GuruFocus rates FRA:6Z4 with a GF Score™ of 50/100 and a GF Value™ of €629.53 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,370 Biotechnology companies, Crinetics Pharmaceuticals ranks better than 90.36% on this metric.

Crinetics Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Crinetics Pharmaceuticals has Crinetics' focus on pharmaceuticals limits direct tariff exposure. While reliant on global suppliers, its specialized products and potential for alternative sourcing reduce vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Crinetics Pharmaceuticals might have Highly Resilient.

Crinetics Pharmaceuticals  (FRA:6Z4) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Crinetics Pharmaceuticals Tariff Resilience Score Related Terms

FRA:6Z4 vs CPRX, NAMS, RCUS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Crinetics Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crinetics Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's Tariff Resilience Score falls into.


FRA:6Z4
50GF Score
Crinetics Pharmaceuticals Inc FRA:6Z4
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Crinetics Pharmaceuticals (FRA:6Z4) has a Tariff Resilience Score of 7 as of Jul. 20, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Crinetics Pharmaceuticals' Tariff Resilience Score too high?
Crinetics Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Crinetics Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Tariff Resilience Score compare to CPRX and NAMS?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #132 out of 1370 companies for Tariff Resilience Score. This places Crinetics Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Crinetics Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (FRA:6Z4) is currently considered Possible Value Trap. The stock's GF Value™ is €629.53, compared to a current price of €70.90 — trading 88.7% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Crinetics Pharmaceuticals' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Tariff Resilience Score is 7 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of €70.90 is trading 88.7% below its estimated GF Value™ of €629.53. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:6Z4:

  • Tariff Resilience Score: 7
  • GF Value™: €629.53 vs. price of €70.90 (88.7% below fair value)
  • GF Score™: 50/100 with 7 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1370)

No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges CRNX:USA
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
50GF Score

Get the complete analysis for FRA:6Z4

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.90
Price
€629.53
GF Value